News
FDA Accepts NDA for Giredestrant/Everolimus in ESR1-Mutated Breast Cancer
9+ hour, 40+ min ago (504+ words) A Prescription Drug User Fee Act date of December 18, 2026, has been set for giredestrant plus everolimus in ER+, HER2, ESR1-mutated breast cancer. The FDA had accepted a new drug application for giredestrant plus everolimus (Afinitor) for the treatment of patients with…...
Standardizing Clinical Breast Examination in Low-and Middle-Income Countries
3+ week, 16+ hour ago (634+ words) Standardizing Clinical Breast Examination in Low-and Middle-Income Countries'CancerNetwork In low- and middle-income countries, the landscape of breast cancer care is often defined by late-stage presentation. While clinicians in high-income countries often utilize mammography to detect sub-centimeter lesions, many LMICs face…...
Recurrence Rates Higher With Axillary Lymph Node Biopsy After NAT Chemo
1+ mon, 2+ week ago (421+ words) Patients with ypN1mi disease on sentinel lymph node biopsy (SLNB) treated with nodal radiotherapy should not receive axillary lymph node dissection (ALND), according to an observational study (NCT06529302) published in The Lancet Oncology. At a median follow-up of 3.1 years, there were 0.4% isolated…...